VETORYL(R) (Trilostane) Receives FDA Approval

Tuesday, December 16, 2008 General News J E 4
OVERLAND PARK, Kan., Dec. 15 Dechra Veterinary ProductsLLC today announces that the company has received FDA approval to marketVETORYL(R) Capsules.

VETORYL Capsules contain the drug trilostane, which has been demonstratedto be effective in the treatment of Cushing's syndrome in dogs. VETORYL willbe indicated for use in pituitary-dependent hyperadrenocorticism, whichcomprises the majority of cases of Cushing's syndrome in dogs. Additionally,VETORYL has received designation status as a Minor Use Drug for treatment ofhyperadrenocorticism caused by adrenal tumors -- the first drug to receive anapproval for this indication and the first drug to receive a Minor Usedesignation in dogs.

Mike Eldred, President of U.S. Operations, says, "We are very excited tohave approval to market this novel product in the U.S. Following its launch inJanuary, veterinarians will be able to source the product through our networkof distribution partners."

Dechra Veterinary Products LLC, located in Overland Park, Kansas, is theU.S. subsidiary of Dechra Pharmaceuticals PLC, a UK listed company focused oninternational animal healthcare markets. Dechra currently markets a range ofspecialized veterinary products in the U.S. For more information, please visit or call 866-933-2472.

SOURCE Dechra Veterinary Products LLC


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Inverness Medical Innovations Declares Dividend on...
MassMutual Retirement Services Adds Vice President...